MSB 0.76% $1.31 mesoblast limited

Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain, page-189

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,978 Posts.
    lightbulb Created with Sketch. 1368
    As you should well know, the purpose of having a control that has the same process as the treated group is to keep the trial blinded. As others have pointed out yesterday , there is plenty of science and past data about NA and it's effects.

    Now instead of getting your lessons from well informed hear on HC perhaps it's time to also contribute. The charts that I posted display data about ( LS )
    As a potential Dr you will need to understand LS and the likely benefit to a patient. I note that if a patient was to get our cell therapy they have a reasonable chance of reduced pain by 36 points. What would this mean for the patient? Would you consider that there is a problem enrolling patients knowing that half of them wont get the treatment.



 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.31
Change
-0.010(0.76%)
Mkt cap ! $1.495B
Open High Low Value Volume
$1.31 $1.33 $1.28 $1.819M 1.396M

Buyers (Bids)

No. Vol. Price($)
2 29972 $1.31
 

Sellers (Offers)

Price($) Vol. No.
$1.31 2008 1
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.